Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038670 | 1.00 | ALDH1A1 (0.54) | ALDH1A1GRM5GAASMN1; SMN2CYP1A2 | |
| SCHEMBL921576 | 0.87 | L3MBTL1 (0.54) | SMN1; SMN2CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL126159 | 0.81 | RAB9A (0.68) | GRM5SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL30485981 | 0.81 | RAB9A (0.68) | GRM5SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL19718960 | 0.81 | ADORA1 (0.48) | SMN1; SMN2CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL13489802 | 0.81 | ADORA1 (0.48) | SMN1; SMN2CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL421678 | 0.80 | ALDH1A1 (0.69) | ALDH1A1GRM5GAASMN1; SMN2CYP1A2 | |
| SCHEMBL336194 | 0.80 | SORT1 (0.50) | GRM5CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL1712579 | 0.80 | ALDH1A1 (0.51) | ALDH1A1GRM5GAASMN1; SMN2CYP1A2 | |
| SCHEMBL29510654 | 0.80 | ALDH1A1 (0.51) | ALDH1A1GRM5GAASMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105566-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-05-05 | — | — | US | claimed |
| US-20250084062-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2025-03-13 | — | — | US | disclosed |
| WO-2023127814-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2023-07-06 | — | — | WO | disclosed |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2022-01-25 | — | — | US | disclosed |
| US-20210238198-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-08-05 | — | — | US | disclosed |
| US-10968236-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-07 | — | — | US | disclosed |
| US-10640488-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-05-05 | — | — | US | disclosed |
| US-10640488-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-05-05 | — | — | US | disclosed |
| EP-1636224-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | Prosidion Limited (GB) | 2006-03-22 | — | — | EP | disclosed |
| EP-0988045-B1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NIELSEN PETER EIGIL (DK) | 2006-02-08 | — | — | EP | disclosed |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| WO-2004104001-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| US-6632919-B1 | Bind Watson-Crick base pairs in a double helix; specific for thymidine | Nielsen, Peter (DK) | 2003-10-14 | — | — | US | disclosed |
| EP-0988045-A4 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NIELSEN PETER EIGIL (DK) | 2002-07-24 | — | — | EP | disclosed |
| EP-0988045-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NIELSEN, Peter Eigil (DK) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998052595-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | ALDH1A1 2255/4885GRM5 1383/4885GAA 2104/4885 |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | ALDH1A1 1148/4885GRM5 316/4885GAA 662/4885 |
| US-20210238198-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885GRM5 3233/4885GAA 1899/4885 |
| US-10968236-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885GRM5 3233/4885GAA 1899/4885 |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | DHPS, HSD17B11, GNE | ALDH1A1 300/4885GRM5 1960/4885GAA 652/4885 |
| US-20250084062-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | CHRNA4, CHRNA2, CHRNA5 | ALDH1A1 2062/4885GRM5 168/4885GAA 1719/4885 |
| US-20110105566-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | HAAO, CYP51A1, HPD | ALDH1A1 3321/4885GRM5 603/4885GAA 359/4885 |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GMPS, GNE, DHPS | ALDH1A1 1200/4885GRM5 733/4885GAA 1534/4885 |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | ALDH1A1 720/4885GRM5 2859/4885GAA 80/4885 |
| US-10640488-B2 | Antibacterial compounds | MRPL21, CLPP, NRDC | ALDH1A1 3914/4885GRM5 4436/4885GAA 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.